Patents by Inventor Edgar Schuck

Edgar Schuck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITOR
    Publication number: 20220378706
    Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 1, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Edgar Schuck, Robert Lai, Ishani Savant Landry, Bhaskar Rege, Mai Miyamoto, Sadaharu Kotani, Kanta Horie
  • Pharmaceutical composition comprising PDE9 inhibitor
    Patent number: 11484502
    Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 1, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Edgar Schuck, Robert Lai, Ishani Savant Landry, Bhaskar Rege, Mai Miyamoto, Sadaharu Kotani, Kanta Horie
  • PHARMACEUTICAL COMPOSITION FOR TREATING INSOMNIA
    Publication number: 20220331309
    Abstract: The present invention provides an oral pharmaceutical composition for treating insomnia, comprising lemborexant or a pharmaceutically acceptable salt thereof, wherein a normal dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 to 10 mg per day, provided that a dose of the lemborexant or pharmaceutically acceptable salt thereof is 2.5 mg per day when the pharmaceutical composition is administered to a patient together with the agent capable of moderately or strongly inhibiting CYP3A, and/or a dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 mg per day when the pharmaceutical composition is administered to the patient together with the agent capable of weakly inhibiting CYP3A.
    Type: Application
    Filed: August 19, 2020
    Publication date: October 20, 2022
    Inventors: Ishani Savant Landry, Kenya Nakai, Yukiko Miyajima, Yosuke Nakatani, Takashi Ueno, Edgar Schuck
  • PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITOR
    Publication number: 20200078306
    Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 30, 2018
    Publication date: March 12, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Edgar Schuck, Robert Lai, Ishani Savant Landry, Bhaskar Rege, Mai Miyamoto, Sadaharu Kotani, Kanta Horie